lenalidomide + cyclophosphamide + dexamethasone

lenalidomide + cyclophosphamide + dexamethasone is a combination therapy regimen, specifically the LENDEXAL regimen, investigated by the PETHEMA Foundation for the treatment of newly diagnosed primary systemic amyloidosis (AL amyloidosis) in patients who are not candidates for autologous stem cell transplantation. The regimen consists of lenalidomide, an immunomodulatory drug (IMiD) that acts as a molecular glue to bind cereblon (CRBN) and induce the degradation of transcription factors like Ikaros and Aiolos; cyclophosphamide, an alkylating agent that cross-links DNA to inhibit replication; and dexamethasone, a potent glucocorticoid that induces apoptosis in malignant plasma cells. This triplet combination aims to achieve deep hematological responses by targeting the underlying clonal plasma cell dyscrasia responsible for the production of amyloidogenic light chains.

Other names

Len-Cy-DexRCD